The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 20, 2016
Filed:
Jun. 04, 2012
Christopher Breuer, New Albany, OH (US);
Tarek Fahmy, New Haven, CT (US);
Michael Simons, Hamden, CT (US);
Pei-yu Chen, East Haven, CT (US);
Daniel Rowe Duncan, Boston, MA (US);
Joseph Patterson, New Haven, CT (US);
Christopher Breuer, New Albany, OH (US);
Tarek Fahmy, New Haven, CT (US);
Michael Simons, Hamden, CT (US);
Pei-Yu Chen, East Haven, CT (US);
Daniel Rowe Duncan, Boston, MA (US);
Joseph Patterson, New Haven, CT (US);
Yale University, New Haven, CT (US);
Abstract
Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.